RXDX [NASD]
Prometheus Biosciences, Inc.
Index- P/E- EPS (ttm)-3.35 Insider Own0.20% Shs Outstand41.22M Perf Week-0.92%
Market Cap5.25B Forward P/E- EPS next Y-3.62 Insider Trans-24.70% Shs Float37.38M Perf Month5.17%
Income-132.90M PEG- EPS next Q-0.91 Inst Own72.70% Short Float / Ratio10.33% / 4.29 Perf Quarter114.36%
Sales7.20M P/S728.95 EPS this Y-244.40% Inst Trans8.73% Short Interest3.86M Perf Half Y168.97%
Book/sh5.64 P/B20.35 EPS next Y-4.60% ROA-50.30% Target Price146.18 Perf Year248.84%
Cash/sh5.69 P/C20.17 EPS next 5Y- ROE-61.40% 52W Range21.50 - 122.75 Perf YTD4.34%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-6.50% Beta-
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low433.81% ATR5.30
Employees72 Current Ratio11.20 Sales Q/Q0.00% Oper. Margin- RSI (14)58.47 Volatility4.59% 4.45%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.50% Profit Margin- Rel Volume0.52 Prev Close116.12
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume899.94K Price114.77
Recom1.50 SMA201.07% SMA5026.29% SMA200116.59% Volume465,041 Change-1.16%
Jul-20-22Initiated Goldman Buy $51
Jun-10-22Initiated Piper Sandler Overweight $53
Feb-11-22Initiated BTIG Research Buy $62
Dec-13-21Initiated RBC Capital Mkts Outperform $46
Dec-08-21Upgrade Oppenheimer Perform → Outperform $35 → $50
Dec-08-21Initiated Wells Fargo Overweight $42
Nov-15-21Downgrade Oppenheimer Outperform → Perform $35
Nov-12-21Resumed Stifel Buy $45
Oct-05-21Initiated Oppenheimer Outperform $35
Apr-26-21Resumed Credit Suisse Outperform $30
Show Previous Ratings
Jan-16-23 07:42AM
Jan-13-23 12:32PM
Jan-10-23 09:55AM
Jan-03-23 08:30AM
Dec-23-22 07:02AM
03:02PM Loading…
Dec-13-22 03:02PM
Dec-09-22 05:32AM
Dec-08-22 07:39PM
12:12PM
Dec-07-22 04:13PM
04:01PM
12:16PM
08:31AM
08:29AM
07:00AM
11:48AM Loading…
Dec-02-22 11:48AM
Nov-12-22 07:52AM
Nov-09-22 05:25PM
04:01PM
Nov-01-22 08:00AM
Oct-12-22 07:54AM
Oct-03-22 08:30AM
Sep-20-22 05:31AM
Sep-15-22 03:00PM
Sep-08-22 11:14AM
Aug-31-22 04:00PM
Aug-29-22 12:00PM
Aug-11-22 05:15PM
04:00PM
Jul-24-22 05:04AM
04:00PM Loading…
Jul-18-22 04:00PM
08:00AM
Jul-14-22 02:41PM
Jun-22-22 09:54AM
Jun-08-22 08:00AM
May-26-22 08:00AM
May-12-22 05:15PM
04:01PM
May-05-22 07:23AM
Mar-30-22 08:00AM
Mar-09-22 04:01PM
Mar-01-22 08:30AM
Feb-07-22 05:38PM
08:00AM
Jan-19-22 04:30AM
Jan-12-22 08:30AM
Jan-05-22 08:30AM
Jan-03-22 08:00AM
Dec-13-21 12:50PM
Dec-07-21 07:00AM
Nov-12-21 08:00AM
Nov-02-21 08:00AM
Oct-12-21 04:01PM
Oct-06-21 06:13AM
Aug-13-21 05:06AM
Aug-11-21 04:01PM
Aug-05-21 07:30AM
Aug-02-21 08:00AM
Jul-19-21 12:50PM
08:00AM
Jul-15-21 08:00AM
Jun-21-21 09:00AM
Jun-14-21 06:59AM
May-25-21 04:05PM
May-17-21 08:00AM
May-14-21 04:01PM
May-13-21 04:01PM
Apr-07-21 10:34AM
Mar-16-21 04:05PM
Mar-11-21 10:26PM
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marshall Keith WChief Financial OfficerJan 17Option Exercise3.705,00018,50014,811Jan 19 08:42 PM
McKenna Mark C.Chairman, President & CEOJan 17Option Exercise2.9025,00072,50080,144Jan 19 08:39 PM
Marshall Keith WChief Financial OfficerJan 17Sale119.005,000595,0009,811Jan 19 08:42 PM
McKenna Mark C.Chairman, President & CEOJan 17Sale118.9925,0002,974,75055,144Jan 19 08:39 PM